AngioDynamics reports Q3 adjusted EPS (7c), consensus (11c)

Reports Q3 revenue $78.4M, consensus $76.77M. “We delivered a strong quarter, driven by continued execution across the organization, allowing us to deliver yet another quarter of profitable growth,” commented CEO Jim Clemmer. “Our mechanical thrombectomy portfolio exhibited standout performance as commercial adoption continues to build with both AlphaVac and AngioVac, confirming our belief that we have the strongest mechanical thrombectomy portfolio available. Auryon remains a consistent growth driver, and NanoKnife is accelerating adoption as we see our commercial strategy supported by the recently effective CPT 1 code for prostate. Beyond the demonstrated topline growth in our higher margin Med Tech businesses, the disciplined execution of our operating initiatives translated into another quarter of strong positive adjusted EBITDA. Our year-to-date performance gives us confidence in our ability to continue to deliver on our strategy and vision. The progress we have made over the past several years is showing up in our results, and we remain focused on driving sustained, profitable growth as we head into Q4 and FY27.”